TG Therapeutics, Inc. - Shareholder/Analyst Call Transcript
Okay. So we've got a great panel. I'm Mike Weiss, I'm the CEO of TG. Thank you all for joining us.
To my right, I've got my co-moderator and Cantor biotech analyst, Alethia Young. Give it up. And then for our panel, we have the first chair, Pier Luigi Zinzani from Bologna, Italy. All the way from Bologna, Italy, gracing us. A world leader in indolent lymphomas, marginal zone, follicular, and I'm sure treats diffuse large B-cell as well.
To his right, Dr. Paul Barr, from the University of Rochester. Yes? That was University of Rochester? Double check. Paul has been involved in TG studies. He's an expert in CLL and lymphoid malignancies generally as well. And was the presenter and lead enroller of -- and really his trial, the Phase I/II for U2 plus venetoclax.
To his right, we have Javier Pinilla from the Moffitt Cancer Center. Also a leader in B-cell malignancies, CLL and other lymphoid malignancies as well, I'm sure. Javier has been a lead enroller in a lot of our clinical trials and also is a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |